Dual-listed cancer diagnostics company Pacific Edge has warned the risk of a non-coverage decision from Medicare for its Cxbladder product is now “more elevated than we assessed for much of the last year”.
Meanwhile, test volumes in the second quarter of the 2024 financial year have fallen 12%,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
